Zeqmelit® was launched in the Nordics in September 2024 and has since received a positive response from the medical community. The new order from Unimedic Pharma, AcuCort’s Nordic distribution partner, relates to the Nordic market.

“The Nordic market is developing strongly, particularly now as allergy season leads to an increased number of healthcare visits. We are seeing strong support from physicians for our product. Our Nordic distribution partner Unimedic Pharma is doing an excellent job in the field – their knowledge, presence, and commitment are an important part of our success,” says Jonas Jönmark, CEO of AcuCort.
 

The order value amounts to EUR 60,385 and is expected to have a positive impact on AcuCort’s results. 
As previously communicated by AcuCort, the company received an order from Unimedic Pharma for the Danish market in April 2025.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.